BR0308431A - Parecoxib sódico cristalino - Google Patents

Parecoxib sódico cristalino

Info

Publication number
BR0308431A
BR0308431A BR0308431-0A BR0308431A BR0308431A BR 0308431 A BR0308431 A BR 0308431A BR 0308431 A BR0308431 A BR 0308431A BR 0308431 A BR0308431 A BR 0308431A
Authority
BR
Brazil
Prior art keywords
parecoxib
unsolvated
slurry
crystalline
parecoxib sodium
Prior art date
Application number
BR0308431-0A
Other languages
English (en)
Inventor
Ahmad Y Sheikh
Thomas R Borchardt
Leonard J Ferro
Gerald D Danzer
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0308431A publication Critical patent/BR0308431A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PARECOXIB SóDICO CRISTALINO". A presente invenção refere-se a parecoxib sódico em uma forma cristalina que é substancialmente anidra e substancialmente não-solvatada . Várias de tais formas cristalinas anidras não-solvatadas foram agora identificadas, incluindo as formas A, B e E conforme aqui descrito. é também proporcionada uma substância de droga parecoxib sódico em que pelo menos cerca de 90% do parecoxib sódico está em uma ou mais formas cristalinas anidras não-solvatadas. Uma tal substância de droga é um intermediário estável no armazenamento que pode ser ainda processado, por exemplo por dissolução ou feitura de uma pasta fluida em um meio aquoso em conjunto com um ou mais excipientes parentericamente aceitáveis, seguido por liofilização da solução ou pasta fluida resultante para proporcionar uma composição injetável reconstituível adequada para uso terapêutico.
BR0308431-0A 2002-03-15 2003-03-12 Parecoxib sódico cristalino BR0308431A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36456702P 2002-03-15 2002-03-15
US41798702P 2002-10-11 2002-10-11
PCT/US2003/007484 WO2003078408A1 (en) 2002-03-15 2003-03-12 Crystalline parecoxib sodium

Publications (1)

Publication Number Publication Date
BR0308431A true BR0308431A (pt) 2005-01-18

Family

ID=28045416

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308431-0A BR0308431A (pt) 2002-03-15 2003-03-12 Parecoxib sódico cristalino

Country Status (18)

Country Link
US (1) US20030232871A1 (pt)
EP (1) EP1485362A1 (pt)
JP (1) JP2005529084A (pt)
KR (1) KR100763045B1 (pt)
CN (1) CN1642926A (pt)
AR (1) AR038985A1 (pt)
AU (1) AU2003220180A1 (pt)
BR (1) BR0308431A (pt)
CA (1) CA2478500A1 (pt)
CO (1) CO5631437A2 (pt)
IL (1) IL163780A0 (pt)
MX (1) MXPA04008932A (pt)
MY (1) MY148518A (pt)
NZ (1) NZ535951A (pt)
PL (1) PL372880A1 (pt)
RU (1) RU2300529C2 (pt)
TW (1) TW200400949A (pt)
WO (1) WO2003078408A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143431A1 (en) * 2003-04-04 2005-06-30 Hetero Drugs Limited Novel crystalline forms of parecoxib sodium
US7268109B2 (en) 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
CA2551523A1 (en) * 2003-12-24 2005-07-21 Pharmacia Corporation Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
US7796785B2 (en) * 2005-03-03 2010-09-14 Fujifilm Corporation Image extracting apparatus, image extracting method, and image extracting program
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
CN105726496B (zh) * 2014-12-12 2019-05-28 湖南科伦药物研究有限公司 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN106580893A (zh) * 2016-12-26 2017-04-26 上药东英（江苏）药业有限公司 一种帕瑞昔布钠冻干粉针制剂
CN106692079A (zh) * 2016-12-26 2017-05-24 上药东英（江苏）药业有限公司 一种帕瑞昔布钠长效冻干粉针制剂
CN117003769A (zh) * 2023-07-11 2023-11-07 宁波慈溪生物医学工程研究所 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1288206B1 (en) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
US7695736B2 (en) * 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
EP1438300A1 (en) * 2001-10-02 2004-07-21 Pharmacia Corporation Method for preparing benzenesulfonyl compounds

Also Published As

Publication number Publication date
RU2004127585A (ru) 2005-04-10
CO5631437A2 (es) 2006-04-28
CA2478500A1 (en) 2003-09-25
JP2005529084A (ja) 2005-09-29
CN1642926A (zh) 2005-07-20
KR100763045B1 (ko) 2007-10-04
AR038985A1 (es) 2005-02-02
EP1485362A1 (en) 2004-12-15
RU2300529C2 (ru) 2007-06-10
PL372880A1 (en) 2005-08-08
MXPA04008932A (es) 2004-11-26
IL163780A0 (en) 2005-12-18
TW200400949A (en) 2004-01-16
AU2003220180A1 (en) 2003-09-29
NZ535951A (en) 2006-02-24
MY148518A (en) 2013-04-30
US20030232871A1 (en) 2003-12-18
KR20040095288A (ko) 2004-11-12
WO2003078408A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
BR0308431A (pt) Parecoxib sódico cristalino
BR112015022483A2 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
AR014886A1 (es) 4,5-diarilimidazoles 2-substituidos, composiciones farmaceuticas que los contienen y su uso para la manufactura de medicamentos
HN2005000484A (es) Nuevas composiciones farmaceuticas para el tratamiento de trastornos hiperproliferativos
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
BRPI0415639A (pt) formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
BR0317463A (pt) Métodos de triar para um composto que evita ou reduz a dissolução de um tetrâmero de transtiretina e de tratar uma doença amilóide transtiretina
AR022076A1 (es) Composicion antioxidante constituida por acetil l-carnitina y acido alfa-lipoico para mejorar el aprovechamiento metabolico de la glucosa
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
BRPI0508392A (pt) materiais e métodos para tratar distúrbios de coagulação
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BRPI0518785A2 (pt) composto de anel de 7 membros e mÉtodo de produÇço e aplicaÇço farmacÊutica do mesmo
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
NO20022201L (no) Lösninger inneholdende Epinastin
DOP2019000228A (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
BR0008657A (pt) Comprimidos deglutìveis com teor elevado den-acetilcisteì na e processo para a preparação dosmesmos
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
NO20021160D0 (no) Bestanddeler

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.